Nxera Pharma
4565.TPharmaceutical
Filed as Sosei Group Corporation (2022-08–2024-03)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥19.0bn | ¥6.6bn | ¥5.0bn | ¥1.1bn | ¥823m | ¥433m |
| Operating income | ¥2.6bn | −¥4.6bn | −¥335m | −¥1.1bn | −¥1.2bn | — |
| Ordinary income | ¥713m | −¥1.5bn | −¥3.3bn | −¥1.6bn | −¥4.7bn | −¥1.4bn |
| Total assets | ¥105.0bn | ¥136.1bn | ¥142.0bn | ¥89.4bn | ¥94.3bn | ¥78.9bn |
| Net assets / equity | ¥44.9bn | ¥68.1bn | ¥65.2bn | ¥57.5bn | ¥58.5bn | ¥61.5bn |
| EPS (basic) | ¥-262.41 | ¥23.89 | ¥-39.81 | ¥-18.3 | ¥-52.47 | ¥-16.62 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 80 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 196 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 80 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 196 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 102 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 80 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 194 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 102 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 80 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 194 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 102 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 102 figures · EDINET |
32 more reports are still being processed.